Fuji Pharma Co., Ltd. (TYO:4554)

Japan flag Japan · Delayed Price · Currency is JPY
2,250.00
-12.00 (-0.53%)
At close: Feb 13, 2026
Market Cap55.35B +55.8%
Revenue (ttm)54.57B +12.8%
Net Income2.33B -47.0%
EPS95.47 -47.2%
Shares Out24.47M
PE Ratio23.69
Forward PE15.17
Dividend47.00 (2.18%)
Ex-Dividend DateMar 30, 2026
Volume358,700
Average Volume195,975
Open2,247.00
Previous Close2,262.00
Day's Range2,229.00 - 2,343.00
52-Week Range1,180.00 - 2,343.00
Beta0.28
RSI76.81
Earnings DateFeb 5, 2026

About Fuji Pharma

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women, in vitro diagnostics, acute medical care products, and curative medicines, and information regarding pharmaceuticals and health services, as well as contract manufacturing services. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, ... [Read more]

Sector Healthcare
Founded 1965
Employees 1,760
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4554
Full Company Profile

Financial Performance

In fiscal year 2025, Fuji Pharma's revenue was 51.68 billion, an increase of 12.01% compared to the previous year's 46.14 billion. Earnings were 3.00 billion, a decrease of -51.19%.

Financial Statements

News

Alvotech Receives Marketing Approval In Japan For Three New Biosimilars

(RTTNews) - Luxembourg-based biotechnology company Alvotech SA (ALVO) announced Friday that its commercialization partner in Japan, Fuji Pharma Co., Ltd. has received marketing approval for three new ...

5 months ago - Nasdaq

Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility

REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO , ALVO SDB, the "Company")), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients w...

8 months ago - Benzinga

Olic anticipates buoyant demand for contraceptives

The contraceptive market is expected to grow in Southeast Asia, driven by informed individuals' increasing awareness of health issues and a trend of having no children, says Olic (Thailand) Ltd, a sub...

1 year ago - Bangkok Post